The DOI matches its Crossref record; 301 of the 301 references it cites were found in a registry or an index.
NK cells and ILCs in tumor immunotherapy
Open accessAbstract
Cells of the innate immunity play an important role in tumor immunotherapy. Thus, NK cells can control tumor growth and metastatic spread. Thanks to their strong cytolytic activity against tumors, different approaches have been developed for exploiting/harnessing their function in patients with leukemia or solid tumors. Pioneering trials were based on the adoptive transfer of autologous NK cell-enriched cell populations that were expanded in vitro and co-infused with IL-2. Although relevant results were obtained in patients with advanced melanoma, the effect was mostly limited to certain metastatic localizations, particularly to the lung. In addition, the severe IL-2-related toxicity and the preferential IL-2-induced expansion of Treg limited this type of approach. This limitation may be overcome by the use of IL-15, particularly of modified IL-15 molecules to improve its half-life and optimize the biological effects. Other approaches to harness NK cell function include stimulation via TLR, the use of bi- and tri-specific NK cell engagers (BiKE and TriKE) linking activating NK receptors (e.g. CD16) to tumor-associated antigens and even incorporating an IL-15 moiety (TriKE). As recently shown, in tumor patients, NK cells may also express inhibitory checkpoints, primarily PD-1. Accordingly, the therapeutic use of checkpoint inhibitors may unleash NK cells against PD-L1+ tumors. This effect may be predominant and crucial in tumors that have lost HLA cl-I expression, thus resulting “invisible” to T lymphocytes. Additional approaches in which NK cells may represent an important tool for cancer therapy, are to exploit the unique properties of the “adaptive” NK cells. These CD57+ NKG2C+ cells, despite their mature stage and a potent cytolytic activity, maintain a strong proliferating capacity. This property revealed to be crucial in hematopoietic stem cell transplantation (HSCT), particularly in the haplo-HSCT setting, to cure high-risk leukemias. T depleted haplo-HSCT (e.g. from one of the parents) allowed to save the life of thousands of patients lacking a HLA-compatible donor. In this setting, NK cells have been shown to play an essential role against leukemia cells and infections. Another major advance is represented by chimeric antigen receptor (CAR)-engineered NK cells. CAR-NK, different from CAR-T cells, may be obtained from allogeneic donors since they do not cause GvHD. Accordingly, they may represent “off-the-shelf” products to promptly treat tumor patients, with affordable costs. Different from NK cells, helper ILC (ILC1, ILC2 and ILC3), the innate counterpart of T helper cell subsets, remain rather ambiguous with respect to their anti-tumor activity. A possible exception is represented by a subset of ILC3: their frequency in peri-tumoral tissues in patients with NSCLC directly correlates with a better prognosis, possibly reflecting their ability to contribute to the organization of tertiary lymphoid structures, an important site of T cell-mediated anti-tumor responses. It is conceivable that innate immunity may significantly contribute to the major advances that immunotherapy has ensured and will continue to ensure to the cure of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–301 of 301
Mamessier, É., Sylvain, A., Bertucci, F., Castellano, R., Finetti, P., Houvenaeghel, G. F., Charafe‐Jauffret, E., Birnbaum, D., Moretta, A., & Olive, D. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0792 · Cited by 154
Signatures of Human NK Cell Development and Terminal Differentiation
Luetke-Eversloh, M. V., Killig, M., & Romagnani, C. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00499 · Cited by 154
You, F., Wang, Y., Jiang, L., Zhu, X., Chen, D., Yuan, L., An, G., Meng, H., & Yang, L. (2019) · Europe PMC (PubMed Central) · Cited by 151
Vey, N., Karlin, L., Sadot‐Lebouvier, S., Broussais, F., Berton-Rigaud, D., Rey, J., Charbonnier, A., Marie, D., André, P., Paturel, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24832 · Cited by 149
Oevermann, L., Michaelis, S. U., Mezger, M., Lang, P., Toporski, J., Bertaina, A., Zecca, M., Moretta, L., Locatelli, F., & Handgretinger, R. (2014) · Blood · doi:10.1182/blood-2014-03-565069 · Cited by 146
Self-citationCritical Role of p38 and GATA3 in Natural Helper Cell Function
Furusawa, J.-I., Moro, K., Motomura, Y., Okamoto, K., Zhu, J., Takayanagi, H., Kubo, M., & Koyasu, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300379 · Cited by 146
Complement factor P is a ligand for the natural killer cell–activating receptor NKp46
Narni-Mancinelli, É., Gauthier, L., Baratin, M., Guia, S., Fenis, A., Deghmane, A., Rossi, B., Fourquet, P., Escalière, B., Kerdiles, Y. M., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aam9628 · Cited by 144
Eckl, J., Büchner, A., Prinz, P. U., Riesenberg, R., Siegert, S. I., Kammerer, R., Nelson, P. J., & Noeßner, E. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0806-7 · Cited by 142
The Interaction Between Two Worlds: MicroRNAs and Toll-Like Receptors
Bayraktar, R., Bertilaccio, M. T. S., & Calin, G. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01053 · Cited by 142
Pierson, B., & Miller, J. S. (1996) · Blood · doi:10.1182/blood.v88.6.2279.bloodjournal8862279 · Cited by 141
NKp80 Defines a Critical Step during Human Natural Killer Cell Development
Freud, A. G., Keller, K. A., Scoville, S. D., Mundy-Bosse, B. L., Cheng, S., Youssef, Y., Hughes, T. L., Zhang, X., Mo, X. M., Porcu, P., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.095 · Cited by 140
Characterization of tumor infiltrating Natural Killer cell subset
Levi, I., Amsalem, H., Nissan, A., Darash‐Yahana, M., Peretz, T., Mandelboim, O., & Rachmilewitz, J. (2015) · Oncotarget · doi:10.18632/oncotarget.3453 · Cited by 139
Pisegna, S., Pirozzi, G., Piccoli, M., Frati, L., Santoni, A., & Palmieri, G. (2004) · Blood · doi:10.1182/blood-2004-05-1860 · Cited by 139
Bie, Q., Zhang, P., Su, Z., Zheng, D., Ying, X., Wu, Y., Yang, H., Chen, D., Wang, S., & Xu, H. (2014) · Journal of Immunology Research · doi:10.1155/2014/923135 · Cited by 138
Sütlü, T., Stellan, B., Gilljam, M., Quezada, H. C., Nahi, H., Gahrton, G., & Alici, E. (2010) · Cytotherapy · doi:10.3109/14653249.2010.504770 · Cited by 137
Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2
Carmenate, T., Pacios-Michelena, A., Enamorado, M., Moreno, E., García‐Martínez, K., Fuente, D., & León, K. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201895 · Cited by 136
Marcenaro, E., Ferranti, B. C., Falco, M., Moretta, L., & Moretta, A. (2008) · International Immunology · doi:10.1093/intimm/dxn073 · Cited by 136
Self-citationUnique Eomes+ NK Cell Subsets Are Present in Uterus and Decidua During Early Pregnancy
Montaldo, E., Vacca, P., Chiossone, L., Croxatto, D., Loiacono, F., Martini, S., Ferrero, S., Walzer, T., Moretta, L., & Mingari, M. C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00646 · Cited by 136
Self-citationSingle-Stranded RNA Derived from HIV-1 Serves as a Potent Activator of NK Cells
Alter, G., Suscovich, T. J., Teigen, N. C., Meier, A., Streeck, H., Brander, C., & Altfeld, M. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7658 · Cited by 133
Matsumoto, M., Tatematsu, M., Nishikawa, F., Azuma, M., Ishii, N., Morii-Sakai, A., Shime, H., & Seya, T. (2015) · Nature Communications · doi:10.1038/ncomms7280 · Cited by 130
Zhou, X., Li, W., Wu, Y., Han, L., Cao, X., Yang, X.-M., Wang, H., Zhao, W., Zhai, W., Qi, Y., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02821 · Cited by 127
Kiladjian, J., Bourgeois, E., Lobe, I., Braun, T., Visentin, G., Bourhis, J.-H., Fenaux, P., Chouaı̈b, S., & Caignard, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404080 · Cited by 126
Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37
Sarhan, D., Hippen, K. L., Lemire, A. M., Hying, S., Luo, X., Lenvik, T. R., Curtsinger, J., Davis, Z., Zhang, B., Cooley, S., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0498 · Cited by 126
Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more
Chiossone, L., Vienne, M., Kerdiles, Y. M., & Vivier, É. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.003 · Cited by 125
Discovery of specialized NK cell populations infiltrating human melanoma metastases.
de Andrade, L. D., Lu, Y.-H., Luoma, A. M., Ito, Y., Pan, D., Pyrdol, J. W., Yoon, C., Yuan, G.-C., & Wucherpfennig, K. (2019) · JCI Insight · doi:10.1172/jci.insight.133103 · Cited by 124
Li, T., Yi, S., Liu, W., Jia, C., Wang, G., Hua, X., Tai, Y., Zhang, Q., & Chen, G. (2013) · Medical Oncology · doi:10.1007/s12032-013-0663-z · Cited by 121
Kim, Y. H., Girardi, M., Duvic, M. A., Kuzel, T. M., Link, B. K., Pinter‐Brown, L. C., & Rook, A. H. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.12.052 · Cited by 121
Activated innate lymphoid cell populations accumulate in human tumour tissues
Salimi, M., Wang, R., Yao, X., Li, X., Wang, X., Hu, Y., Chang, X., Fan, P., Dong, T., & Ogg, G. S. (2018) · BMC Cancer · doi:10.1186/s12885-018-4262-4 · Cited by 121
Mancusi, A., Ruggeri, L., Urbani, E., Pierini, A., Massei, M. S., Carotti, A., Terenzi, A., Falzetti, F., Tosti, A., Topini, F., et al. (2015) · Blood · doi:10.1182/blood-2014-09-599993 · Cited by 120
Infusions of Allogeneic Natural Killer Cells as Cancer Therapy
Leung, W. H. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1766 · Cited by 120
Schleypen, J., von Geldern, M., Weiss, E., Kotzias, N., Rohrmann, K., Schendel, D., Falk, C., & Pohla, H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11321 · Cited by 118
Sivori, S., Falco, M., Carlomagno, S., Romeo, E., Soldani, C., Bensussan, A., Viola, A., Moretta, L., & Moretta, A. (2010) · Blood · doi:10.1182/blood-2009-12-256586 · Cited by 118
Self-citationNovel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
Chen, K. H., Wada, M., Firor, A. E., Pinz, K. G., Jares, A., Liu, H., Salman, H., Golightly, M. G., Lan, F., Jiang, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11019 · Cited by 118
Immune Adaptation to Environmental Influence: The Case of NK Cells and HCMV
Rölle, A., & Brodin, P. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.005 · Cited by 114
Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer
Davis, Z., Felices, M., Verneris, M. R., & Miller, J. S. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000156 · Cited by 114
Moore, G. L., Bautista, C., Pong, E., Nguyen, D.-H. T., Jacinto, J. M., Eivazi, A., Muchhal, U. S., Karki, S., Chu, S. Y., & Lazar, G. A. (2011) · mAbs · doi:10.4161/mabs.3.6.18123 · Cited by 110
Wagner, J., Pfannenstiel, V., Waldmann, A., Bergs, J. W. J., Brill, B., Huenecke, S., Klingebiel, T. E., Rödel, F., Buchholz, C. J., Wels, W. S., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00676 · Cited by 110
Zheng, Y., Li, Y., Lian, J., Yang, H., Li, F., Zhao, S., Qi, Y., Zhang, Y., & Huang, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1917-0 · Cited by 110
Anti‐tumour immunotherapy with V γ9 V δ2 T lymphocytes: from the bench to the bedside
Braza, M. S., & Klein, B. (2012) · British Journal of Haematology · doi:10.1111/bjh.12090 · Cited by 106
Messaoudene, M., Fregni, G., Fourmentraux-Neves, E., Chanal, J., Maubec, E., Mazouz-Dorval, S., Couturaud, B., Girod, A., Sastre‐Garau, X., Albert, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1303 · Cited by 106
Intratumorally Establishing Type 2 Innate Lymphoid Cells Blocks Tumor Growth
Kim, J., Kim, W., Moon, U. J., Kim, H. J., Choi, H., Sin, J., Park, N. H., Cho, H. R., & Kwon, B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501730 · Cited by 106
Miller, J. S., Tessmer-Tuck, J. A., Pierson, B. A., Weisdorf, D. J., McGlave, P. B., Blazar, B. R., Katsanis, E., Verfaillie, C. M., LEBKOWSKI, J. S., Radford, J., et al. (1997) · PubMed · Cited by 102
Khaznadar, Z., Boissel, N., Agaugué, S., Henry, G., Cheok, M. H.-C., Vignon, M., Géromin, D., Cayuela, J., Castaigné, S., Pautas, C., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500262 · Cited by 101
Quintarelli, C., Sivori, S., Caruso, S., Carlomagno, S., Falco, M., Boffa, I., Orlando, D., Guercio, M., Abbaszadeh, Z., Sinibaldi, M., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0613-7 · Cited by 101
Self-citationMuccio, L., Bertaina, A., Falco, M., Pende, D., Meazza, R., López‐Botet, M., Moretta, L., Locatelli, F., Moretta, A., & Chiesa, M. D. (2015) · Haematologica · doi:10.3324/haematol.2015.134155 · Cited by 100
Self-citationMarkers and function of human NK cells in normal and pathological conditions
del Zotto, G., Marcenaro, E., Vacca, P., Sivori, S., Pende, D., Chiesa, M. D., Moretta, F., Ingegnere, T., Mingari, M., Moretta, A., et al. (2017) · Cytometry. Part B, Clinical cytometry · doi:10.1002/cyto.b.21508 · Cited by 100
Self-citationDutcher, J. P., Gaynor, E. R., Boldt, D. H., Doroshow, J. H., Bar, M. H., Sznol, M., Mier, J. W., Sparano, J. A., Fisher, R. I., & Weiss, G. R. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.4.641 · Cited by 99
A subset of HLA-DP molecules serve as ligands for the natural cytotoxicity receptor NKp44
Niehrs, A., García-Beltrán, W. F., Norman, P. J., Watson, G. M., Hölzemer, A., Chapel, A., Richert, L. E., Pommerening‐Röser, A., Körner, C., Ozawa, M., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0448-4 · Cited by 98
Distinct HLA-E Peptide Complexes Modify Antibody-Driven Effector Functions of Adaptive NK Cells
Rölle, A., Meyer, M., Calderazzo, S., Jäger, D., & Momburg, F. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.069 · Cited by 95
Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function
Scoville, S. D., Nalin, A. P., Chen, L., Chen, L., Zhang, M. H., McConnell, K. K., Casas, S. B., Ernst, G., Traboulsi, A. A.-R., Hashi, N. J., et al. (2018) · Blood · doi:10.1182/blood-2018-03-838474 · Cited by 94
Schmohl, J., Felices, M., Oh, F., Lenvik, A. J., LeBeau, A. M., Panyam, J., Miller, J. S., & Vallera, D. A. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.491 · Cited by 92
Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade
Ohs, I., Ducimetière, L., Marinho, J. C. L., Kulig, P., Becher, B., & Tugues, S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1032 · Cited by 90
Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL
Felices, M., Kodal, B., Hinderlie, P., Kaminski, M. F., Cooley, S., Weisdorf, D. J., Vallera, D. A., Miller, J. S., & Bachanová, V. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018029371 · Cited by 90
Tumino, N., Martini, S., Munari, E., Scordamaglia, F., Besi, F., Mariotti, F. R., Bogina, G. S., Mingari, M. C., Vacca, P., & Moretta, L. (2019) · International Journal of Cancer · doi:10.1002/ijc.32262 · Cited by 86
Self-citationThe Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer
Wang, Z., Zhu, J., Gu, H., Yuan, Y., Zhang, B., Zhu, D., Zhou, J., Zhu, Y., & Chen, W. (2015) · Immunological Investigations · doi:10.3109/08820139.2015.1052145 · Cited by 84
Nidogen-1 is a novel extracellular ligand for the NKp44 activating receptor
Gaggero, S., Bruschi, M., Petretto, A., Parodi, M., Zotto, G. D., Lavarello, C., Prato, C., Santucci, L., Barbuto, A., Bottino, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1470730 · Cited by 84
Self-citationEx Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells
Liu, L. L., Béziat, V., Oei, V. Y. S., Pfefferle, A., Schaffer, M., Lehmann, S., Hellström‐Lindberg, E., Söderhäll, S., Heyman, M. M., Grandér, D., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0296 · Cited by 83
Montaldo, E., Vitale, C., Cottalasso, F., Conte, R., Glatzer, T., Ambrosini, P., Moretta, L., & Mingari, M. C. (2012) · Blood · doi:10.1182/blood-2011-09-379693 · Cited by 81
Self-citationWong, H. C., Jeng, E. K., & Rhode, P. R. (2013) · OncoImmunology · doi:10.4161/onci.26442 · Cited by 80
Adaptive NK cells can persist in patients with GATA2 mutation depleted of stem and progenitor cells
Schlums, H., Jung, M., Han, H., Theorell, J., Bigley, V., Chiang, S. C. C., Allan, D., Davidson-Moncada, J. K., Dickinson, R. E., Holmes, T. D., et al. (2017) · Blood · doi:10.1182/blood-2016-08-734236 · Cited by 80
Adaptive NK cell reconstitution is associated with better clinical outcomes
Cichocki, F. M., Taras, E., Chiuppesi, F., Wagner, J. E., Blazar, B. R., Brunstein, C. G., Luo, X., Diamond, D. J., Cooley, S., Weisdorf, D. J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125553 · Cited by 80
Vitale, M., Cantoni, C., Chiesa, M. D., Ferlazzo, G., Carlomagno, S., Pende, D., Falco, M., Pessino, A., Muccio, L., Maria, A. D., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01415 · Cited by 79
Self-citationTGF-β1 Downregulates the Expression of CX3CR1 by Inducing miR-27a-5p in Primary Human NK Cells
Regis, S., Caliendo, F., Dondero, A., Casu, B., Romano, F., Loiacono, F., Moretta, A., Bottino, C., & Castriconi, R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00868 · Cited by 77
Sivori, S., Carlomagno, S., Moretta, L., & Moretta, A. (2006) · European Journal of Immunology · doi:10.1002/eji.200535781 · Cited by 76
Self-citationSaranchova, I., Han, J. S., Huang, H., Fenninger, F., Choi, K. B., Munro, L., Pfeifer, C. G., Welch, I. D., Wyatt, A. W., Fazli, L., et al. (2016) · Scientific Reports · doi:10.1038/srep30555 · Cited by 74
Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor
Tassev, D. V., Cheng, M., & Cheung, N. K. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.66 · Cited by 72
Mariotti, F., Quatrini, L., Munari, E., Vacca, P., & Moretta, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00910 · Cited by 71
Self-citationSchmohl, J. U., Felices, M., Todhunter, D., Taras, E. P., Miller, J. S., & Vallera, D. A. (2016) · Oncotarget · doi:10.18632/oncotarget.12073 · Cited by 70
Fauriat, C., Moretta, A., Olive, D., & Costello, R. T. (2005) · Blood · doi:10.1182/blood-2005-03-1270 · Cited by 69
NK Cell-Based Immunotherapy for Hematological Malignancies
Sivori, S., Meazza, R., Quintarelli, C., Carlomagno, S., Chiesa, M. D., Falco, M., Moretta, L., Locatelli, F., & Pende, D. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101702 · Cited by 69
Self-citationPira, G. L., Malaspina, D. C., Girolami, E., Biagini, S., Cicchetti, E., Conflitti, G., Broglia, M., Ceccarelli, S., Lazzaro, S., Pagliara, D., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.08.006 · Cited by 68
Self-citationBertaina, A., Zorzoli, A., Petretto, A., Barbarito, G., Inglese, E., Merli, P., Lavarello, C., Brescia, L. P., Angelis, B. D., Tripodi, G., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1216291 · Cited by 66
Self-citationRedondo‐Pachón, D., Crespo, M., Yélamos, J., Muntasell, A., Pérez‐Sáez, M. J., Pérez-Fernández, S., Vila, J., Vilches, C., Pascual, J., & López‐Botet, M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601236 · Cited by 66
Activating killer cell immunoglobulin‐like receptors: Detection, function and therapeutic use
Blunt, M. D., & Khakoo, S. I. (2019) · International Journal of Immunogenetics · doi:10.1111/iji.12461 · Cited by 62
The IL-23 to IL-17 cascade inflammation-related cancers.
Wang, K., & Karin, M. (2015) · PubMed · Cited by 58
Davis, Z., Cooley, S., Cichocki, F. M., Felices, M., Wangen, R., Luo, X., DeFor, T. E., Bryceson, Y. T., Diamond, D. J., Brunstein, C. G., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.05.025 · Cited by 57
Kruit, W. H. J., Punt, K. J., Goey, S. H., de Mulder, P. H., Hoogenhuyze, D. C. A. V., Henzen‐Logmans, S. C., & Stoter, G. (1994) · Cancer · Cited by 55
IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation
Sim, G. C., Liu, C., Wang, E., Liu, H., Creasy, C. A., Dai, Z., Overwijk, W. W., Roszik, J., Marincola, F. M., Hwu, P., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0195 · Cited by 55
Terrén, I., Mikelez-Alonso, I., Odriozola, I., Gredilla, A., González, J., Orrantia, A., Vitallé, J., Zenarruzabeitia, O., & Borrego, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00737 · Cited by 54
Kloeß, S., Oberschmidt, O., Dahlke, J., Vu, X., Neudoerfl, C., Kloos, A., Gardlowski, T., Matthies, N., Heuser, M., Meyer, J., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.247 · Cited by 53
Tumino, N., Besi, F., Pace, A. L. D., Mariotti, F. R., Merli, P., Pira, G. L., Galaverna, F., Pitisci, A., Ingegnere, T., Pelosi, A., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0585-7 · Cited by 48
Self-citationCorat, M. A. F., Schlums, H., Wu, C., Theorell, J., Espinoza, D. A., Sellers, S. E., Townsley, D. M., Young, N. S., Bryceson, Y. T., Dunbar, C. E., et al. (2016) · Blood · doi:10.1182/blood-2016-08-734285 · Cited by 46
Chi-Sabins, N., Chornoguz, O., Leander, K. R., Kaplan, F. M., Carter, R., Kinder, M., Bachman, K. E., Verona, R. I., Shen, S., Bhargava, V., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1701030 · Cited by 45
Bridging Innate NK Cell Functions with Adaptive Immunity
Marcenaro, E., Carlomagno, S., Pesce, S., Moretta, A., & Sivori, S. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-5632-3_5 · Cited by 42
Self-citationParodi, M., Pedrazzi, M., Cantoni, C., Averna, M., Patrone, M., Cavaletto, M., Spertino, S., Pende, D., Balsamo, M., Pietra, G., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1052353 · Cited by 40
Self-citationMuccio, L., Falco, M., Bertaina, A., Locatelli, F., Frassoni, F., Sivori, S., Moretta, L., Moretta, A., & Chiesa, M. D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01050 · Cited by 40
Self-citationUse of adjuvants for immunotherapy
Circelli, L., Tornesello, M. L., Buonaguro, F. M., & Buonaguro, L. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1321725 · Cited by 38
Ribera, J. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1396890 · Cited by 38
Ataya, M., Redondo‐Pachón, D., Llinàs-Mallol, L., Yélamos, J., Heredia, G., Pérez‐Sáez, M. J., Vila, J., Costa-García, M., Regué, D. R., Vilches, C., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15658 · Cited by 37
Hide and seek: Plasticity of innate lymphoid cells in cancer
Bald, T., Wagner, M., Gao, Y., Koyasu, S., & Smyth, M. J. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.04.001 · Cited by 35
The pro- and anti-tumor role of ILC2s
Trabanelli, S., Chevalier, M. F., Derré, L., & Jandus, C. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.04.004 · Cited by 35
Capuano, C., Battella, S., Pighi, C., Franchitti, L., Turriziani, O., Morrone, S., Santoni, A., Galandrini, R., & Palmieri, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01031 · Cited by 31
Polyclonal Expansion of NKG2C+ NK Cells in TAP-Deficient Patients
Béziat, V., Sleiman, M., Goodridge, J. P., Kaarbø, M., Liu, L. L., Rollag, H., Ljunggren, H., Zimmer, J., & Malmberg, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00507 · Cited by 28
Memory NK Cell Features Exploitable in Anticancer Immunotherapy
Capuano, C., Pighi, C., Battella, S., Santoni, A., Palmieri, G., & Galandrini, R. (2019) · Journal of Immunology Research · doi:10.1155/2019/8795673 · Cited by 28
Pupuleku, A., Costa-García, M., Farré, D., Hengel, H., Angulo, A., Muntasell, A., & López‐Botet, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01317 · Cited by 27
Sivori, S., Falco, M., Moretta, L., & Moretta, A. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.05.007 · Cited by 26
Self-citationIL‐1β inhibits ILC3 while favoring NK‐cell maturation of umbilical cord blood CD34 + precursors
Ambrosini, P., Loiacono, F., Conte, R., Moretta, L., Vitale, C., & Mingari, M. C. (2015) · European Journal of Immunology · doi:10.1002/eji.201445326 · Cited by 25
Self-citationAyello, J. S., Hochberg, J. C., Flower, A. M., Chu, Y., Baxi, L., Quish, W., van de Ven, C., & Cairo, M. S. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.10.003 · Cited by 23
Helper Innate Lymphoid Cells in Human Tumors: A Double-Edged Sword?
Tumino, N., Vacca, P., Quatrini, L., Munari, E., Moretta, F., Pelosi, A., Mariotti, F. R., & Moretta, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03140 · Cited by 10
Self-citationGuan, J., Wang, R., Hasan, S., Tao, L., Wazir, M., Jain, A. G., Zhu, X., Perkins, S. L., Salama, M. E., Chang, C.-C., et al. (2019) · Cureus · doi:10.7759/cureus.4401 · Cited by 8
Bischof, A. (2000) · doi:10.1002/1521-4141(200003)30:3
Cited by
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
Peña-Romero, A. C., & Orenes-Piñero, E. (2022) · Cancers · doi:10.3390/cancers14071681 · Cited by 257
Metadata
- Authors
- Sivori, S., Pende, D., Quatrini, L., Pietra, G., Della Chiesa, M., Vacca, P., Tumino, N., Moretta, F., Mingari, M. C., Locatelli, F., & Moretta, L.
- Venue
- Molecular Aspects of Medicine
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 80
- Pages
- 100870
- ISSN
- 0098-2997 (ISSN-L)
- OpenAlex
- W3049733355
- Cited by
- 270
- References
- 301
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.